IL135921A - Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity - Google Patents

Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity

Info

Publication number: IL135921A
Authority: IL; Israel
Prior art keywords: mmp; inhibitory activity; hydroxamic; carboxylic acid; acid derivatives
Prior art date: 1997-11-12

Application number

IL13592198A

Other languages

English (en)

Other versions

IL135921A0 (en

Original Assignee

Darwin Discovery Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-11-12

Filing date

1998-11-12

Publication date

2005-08-31

1997-11-12 Priority claimed from GBGB9723906.5A external-priority patent/GB9723906D0/en

1998-02-06 Priority claimed from GBGB9802618.0A external-priority patent/GB9802618D0/en

1998-06-26 Priority claimed from GBGB9813933.0A external-priority patent/GB9813933D0/en

1998-11-12 Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd

2001-05-20 Publication of IL135921A0 publication Critical patent/IL135921A0/xx

2005-08-31 Publication of IL135921A publication Critical patent/IL135921A/xx

Links

230000002401 inhibitory effect Effects 0.000 title abstract 2
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title 1
150000001732 carboxylic acid derivatives Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Obesity (AREA)
Transplantation (AREA)

IL13592198A 1997-11-12 1998-11-12 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity IL135921A (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GBGB9723906.5A GB9723906D0 (en)	1997-11-12	1997-11-12	Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activiy
GBGB9802618.0A GB9802618D0 (en)	1998-02-06	1998-02-06	Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
GBGB9813933.0A GB9813933D0 (en)	1998-06-26	1998-06-26	Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
PCT/GB1998/003395 WO1999024399A1 (en)	1997-11-12	1998-11-12	Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity

Publications (2)

Publication Number	Publication Date
IL135921A0 IL135921A0 (en)	2001-05-20
IL135921A true IL135921A (en)	2005-08-31

Family

ID=27269088

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL13592198A IL135921A (en)	1997-11-12	1998-11-12	Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity

Country Status (18)

Country	Link
EP (1)	EP1030836B1 (de)
JP (1)	JP2001522832A (de)
KR (1)	KR100609926B1 (de)
CN (1)	CN1283183A (de)
AT (1)	ATE231837T1 (de)
AU (1)	AU748843B2 (de)
BR (1)	BR9814147A (de)
CA (1)	CA2308359A1 (de)
DE (1)	DE69811111T2 (de)
DK (1)	DK1030836T3 (de)
ES (1)	ES2190115T3 (de)
HU (1)	HUP0100152A3 (de)
IL (1)	IL135921A (de)
NO (1)	NO20002440L (de)
NZ (1)	NZ504387A (de)
PL (1)	PL340551A1 (de)
RU (1)	RU2210567C2 (de)
WO (1)	WO1999024399A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU721748B2 (en) *	1997-02-03	2000-07-13	Pfizer Products Inc.	Arylsulfonylamino hydroxamic acid derivatives
GB9801690D0 (en)	1998-01-27	1998-03-25	Pfizer Ltd	Therapeutic agents
US6479502B1 (en)	1998-08-29	2002-11-12	British Biotech Pharmaceuticals	Hydroxamic acid derivatives as proteinase inhibitors
US6706719B1 (en)	1998-11-12	2004-03-16	Darwin Discovery, Ltd.	Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
AP2001002240A0 (en) *	1999-02-08	2001-09-30	Searle & Co	Sufamato hydroxamic acid metalloprotease inhibitor.
US6800646B1 (en)	1999-02-08	2004-10-05	Pharmacia Corporation	Sulfamato hydroxamic acid metalloprotease inhibitor
GB9929527D0 (en) *	1999-12-14	2000-02-09	Smithkline Beecham Plc	Novel compounds
EP1286994A1 (de) *	2000-05-15	2003-03-05	Darwin Discovery Limited	Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung
JP2003533513A (ja)	2000-05-15	2003-11-11	ダーウィン・ディスカバリー・リミテッド	Ｍｍｐおよびｔｎｆ阻害活性を有するヒドロキサム酸およびカルボン酸誘導体
WO2001087870A1 (en) *	2000-05-15	2001-11-22	Darwin Discovery Limited	Hydroxamic acid derivatives
JP4975941B2 (ja)	2000-09-29	2012-07-11	トポターゲットユーケーリミテッド	（ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途
WO2002026696A1 (en)	2000-09-29	2002-04-04	Prolifix Limited	Carbamic acid compounds comprising an amide linkage as hdac inhibitors
JP2004527511A (ja) *	2001-03-15	2004-09-09	アストラゼネカ・アクチエボラーグ	メタロプロテイナーゼ阻害剤
SE0100902D0 (sv) *	2001-03-15	2001-03-15	Astrazeneca Ab	Compounds
GB0119396D0 (en) *	2001-08-09	2001-10-03	Celltech R&D Ltd	Hydroxamic acid derivatives
SE0103710D0 (sv)	2001-11-07	2001-11-07	Astrazeneca Ab	Compounds
PE20030701A1 (es)	2001-12-20	2003-08-21	Schering Corp	Compuestos para el tratamiento de trastornos inflamatorios
BR0308908A (pt)	2002-04-03	2005-01-04	Topotarget Uk Ltd	Composto, composição, uso de um composto, e, métodos para inibir a hdac em uma célula, para o tratamento de uma condição mediada pela hdac, de um condição proliferativa, de câncer e de psorìase
BR0309671A (pt)	2002-04-25	2005-05-03	Pharmacia Corp	ácidos de piperidinil- e piperazinil-sulfonilmetil hidroxâmicos e seu uso como inibidores de protease
GB0216383D0 (en) *	2002-07-13	2002-08-21	Astrazeneca Ab	Compounds
GB0216382D0 (en) *	2002-07-13	2002-08-21	Astrazeneca Ab	Compounds
SE0202539D0 (sv)	2002-08-27	2002-08-27	Astrazeneca Ab	Compounds
AU2004205372B2 (en)	2003-01-17	2011-02-24	Topotarget Uk Limited	Hydroxamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors
US7648992B2 (en)	2004-07-05	2010-01-19	Astrazeneca Ab	Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv)	2004-07-05	2004-07-05	Astrazeneca Ab	Novel compounds
RU2277418C1 (ru) *	2004-12-08	2006-06-10	Государственное научное учреждение (ГНУ) Всероссийский научно-исследовательский ветеринарный институт патологии, фармакологии и терапии (ВНИВИПФиТ)	Препарат для лечения бронхопневмонии у телят
SE0403085D0 (sv)	2004-12-17	2004-12-17	Astrazeneca Ab	Novel componds
SE0403086D0 (sv)	2004-12-17	2004-12-17	Astrazeneca Ab	Compounds
RU2286141C1 (ru) *	2005-03-03	2006-10-27	Общество с ограниченной ответственностью "Фарм-Лад"	Мазь для наружного применения
WO2008008398A2 (en) *	2006-07-14	2008-01-17	Shionogi & Co., Ltd.	Oxime compounds and the use thereof
ES2422603T3 (es)	2007-05-31	2013-09-12	Shionogi & Co	Compuestos oxiimino y el uso de estos
WO2009151152A1 (en)	2008-06-11	2009-12-17	Shionogi & Co., Ltd.	Oxycarbamoyl compounds and the use thereof
KR20220164216A (ko) *	2021-06-04	2022-12-13	에스티팜 주식회사	신규한 에르고스텐올 유도체 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1067965A (en) *	1965-01-22	1967-05-10	Beecham Group Ltd	Penicillins, esters, amides and salts thereof
US5239079A (en) *	1988-05-12	1993-08-24	Eisai Co., Ltd.	Pyridinium salt and pharmacological composition containing the same
ATE225343T1 (de) *	1995-12-20	2002-10-15	Hoffmann La Roche	Matrix-metalloprotease inhibitoren

1998
- 1998-11-12 KR KR1020007005163A patent/KR100609926B1/ko not_active Expired - Fee Related
- 1998-11-12 ES ES98952927T patent/ES2190115T3/es not_active Expired - Lifetime
- 1998-11-12 JP JP2000520413A patent/JP2001522832A/ja active Pending
- 1998-11-12 AU AU10469/99A patent/AU748843B2/en not_active Ceased
- 1998-11-12 BR BR9814147-3A patent/BR9814147A/pt not_active IP Right Cessation
- 1998-11-12 WO PCT/GB1998/003395 patent/WO1999024399A1/en not_active Ceased
- 1998-11-12 CN CN98812677A patent/CN1283183A/zh active Pending
- 1998-11-12 PL PL98340551A patent/PL340551A1/xx not_active Application Discontinuation
- 1998-11-12 DE DE69811111T patent/DE69811111T2/de not_active Expired - Fee Related
- 1998-11-12 CA CA002308359A patent/CA2308359A1/en not_active Abandoned
- 1998-11-12 RU RU2000114881/04A patent/RU2210567C2/ru not_active IP Right Cessation
- 1998-11-12 HU HU0100152A patent/HUP0100152A3/hu unknown
- 1998-11-12 IL IL13592198A patent/IL135921A/xx not_active IP Right Cessation
- 1998-11-12 NZ NZ504387A patent/NZ504387A/xx unknown
- 1998-11-12 AT AT98952927T patent/ATE231837T1/de not_active IP Right Cessation
- 1998-11-12 DK DK98952927T patent/DK1030836T3/da active
- 1998-11-12 EP EP98952927A patent/EP1030836B1/de not_active Expired - Lifetime
2000
- 2000-05-11 NO NO20002440A patent/NO20002440L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
PL340551A1 (en)	2001-02-12
KR100609926B1 (ko)	2006-08-04
CN1283183A (zh)	2001-02-07
EP1030836A1 (de)	2000-08-30
HUP0100152A2 (hu)	2002-02-28
ATE231837T1 (de)	2003-02-15
DK1030836T3 (da)	2003-05-26
IL135921A0 (en)	2001-05-20
HUP0100152A3 (en)	2002-07-29
ES2190115T3 (es)	2003-07-16
KR20010032042A (ko)	2001-04-16
JP2001522832A (ja)	2001-11-20
NO20002440D0 (no)	2000-05-11
DE69811111T2 (de)	2003-07-24
EP1030836B1 (de)	2003-01-29
AU1046999A (en)	1999-05-31
BR9814147A (pt)	2000-10-03
DE69811111D1 (de)	2003-03-06
CA2308359A1 (en)	1999-05-20
NZ504387A (en)	2002-10-25
RU2210567C2 (ru)	2003-08-20
AU748843B2 (en)	2002-06-13
WO1999024399A1 (en)	1999-05-20
NO20002440L (no)	2000-05-11

Legal Events

Date	Code	Title
2006-02-21	FF	Patent granted
2006-04-10	KB	Patent renewed
2010-02-14	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
IL135921A0 (en)	2001-05-20	Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
NZ335981A (en)	2000-04-28	Ketobenzamides as calpain inhibitors
GR3030751T3 (en)	1999-11-30	Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
MX9603520A (es)	1998-01-31	Derivados del acido hidroxamico y acido carboxilico, procesos para su preparacion y su uso.
NZ332762A (en)	2000-09-29	Isobutylgaba and its derivatives for the treatment of pain
AU6613896A (en)	1996-10-30	Chemical compounds
GB9801690D0 (en)	1998-03-25	Therapeutic agents
AU3202595A (en)	1996-02-22	1,2-substituted imidazolyl compounds for the treatment of inflammation
ZA9710796B (en)	1998-06-12	Oxyiminopregnanecarbolactones.
MX9702658A (es)	1997-06-28	Derivados novedosos de acido carboxilico, su preparacion y uso.
MY131657A (en)	2007-08-30	Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
BR9808214A (pt)	2000-05-16	Compostos de n-hidróxi 4-sulfonil butanamida
GB0105772D0 (en)	2001-04-25	Use
IE862404L (en)	1987-03-10	Hydroxamic acid derivatives
PL343495A1 (en)	2001-08-27	Heterocyclically substituted amides used as calpain inhibitors
CA2268484A1 (en)	1999-10-10	Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives
FI925787A0 (fi)	1992-12-18	Proteolytiska enzymers sackarinderivatinhibitorer
BG103399A (en)	2000-01-31	New heterocycle-substituted benzamides and their application for the treatment of diseases
NZ513096A (en)	2003-01-31	Compositions for treating inflammatory response
ZA978400B (en)	1998-03-26	Use of inhibitors of the activity of retinoic acid to promote healing.
IL150125A0 (en)	2002-12-01	Novel compounds
ES8707553A1 (es)	1987-08-01	Procedimiento para la obtencion de un peptido.
ATE286892T1 (de)	2005-01-15	Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität
GB9723905D0 (en)	1998-01-07	Heterocyclic compounds having MMP and TNF inhibitory activity
FR2657005B1 (fr)	1992-05-29	Systeme d'enclouage pour le traitement des fractures notamment du type cervico-trochanteriennes et pertrochanteriennes.